News about Global Pharma

AltrixBio Raises USD 5 Million Series A Financing and Appoints David Pass as CEO

Dr David Pass, a veteran of the pharma, biotech, and medical device sectors with a track record of scaling programs to over USD 1 billion in sales, succeeds AltrixBio Co-Founder and CEO Nancy Briefs, who led the company from inception and will now serve as Executive Chair.

Global Pharma | 18/09/2025 | By Dineshwori |  322

Biocon Biologics Secures US FDA Approval for Denosumab Biosimilars Bosaya and Aukelso

The US Food and Drug Administration (FDA) has approved Biocon Biologics' denosumab biosimilars, Bosaya (denosumab-kyqq) 60 mg/mL injection in a single-dose prefilled syringe (PFS) and Aukelso (denosumab-kyqq) 120 mg/1.7 mL (70 mg/mL) injection in a single-dose vial, biosimilars of Prolia and Xgeva, respectively.

Global Pharma | 17/09/2025 | By Dineshwori |  441

GAIASO Theranostics Appoints Dr. Tracey Brown as New CEO

GAIASO Theranostics, an Australia-based biotech company pioneering next-generation precision radiopharmaceuticals for women’s cancers, has appointed Dr. Tracey Brown as its new Chief Executive Officer (CEO).

Global Pharma | 17/09/2025 | By Dineshwori |  355

Lupin Secures US FDA Approval for Lenalidomide Capsules

The approved Lenalidomide Capsules, bioequivalent to Revlimid by Bristol-Myers Squibb, will be produced at Lupin’s Pithampur site in India.

Global Pharma | 17/09/2025 | By Dineshwori |  311

Lilly to Establish USD 5 Billion API Manufacturing Facility in Virginia

The new site in Virginia marks the first of four new US manufacturing sites that Lilly plans to announce this year.

Global Pharma | 17/09/2025 | By Dineshwori |  178

FDA Grants BTD to Raludotatug Deruxtecan for Platinum-Resistant Ovarian Cancer

This is the first BTD granted for Raludotatug Deruxtecan, the second for the Daiichi Sankyo-Merck partnership and the 15th across Daiichi Sankyo’s oncology portfolio, marking a significant milestone in the companies’ joint efforts to develop innovative cancer therapies.

Global Pharma | 16/09/2025 | By Dineshwori |  230

India's Pharma Exports Rise Nearly 7 percent in August 2025

India’s exports of drugs and pharmaceuticals climbed 6.94 percent from USD 2.35 billion in August 2024 to USD 2.51 billion in August 2025.

Global Pharma | 16/09/2025 | By Dineshwori |  571

Atavistik Bio Appoints Dr. Susan Pandya as Chief Medical Officer

As CMO, Dr. Susan Pandya will lead all clinical development strategy and execution for Atavistik Bio, including the ongoing Phase 1 clinical trial of its lead programme, ATV-1601.

Global Pharma | 15/09/2025 | By Dineshwori |  190

Mycenax, SPERA PHARMA Form Alliance to Streamline ADC Manufacturing

Mycenax Biotech has formed a strategic alliance with Japan’s SPERA PHARMA to provide an integrated end-to-end development and manufacturing platform for antibody-drug conjugates (ADCs) and bioconjugates.

Global Pharma | 15/09/2025 | By Mrinmoy Dey |  151

Mesoblast Launches FDA-Approved Ryoncil for Pediatric Graft Versus Host Disease

Mesoblast has announced the commercial launch of Ryoncil (remestemcel-L-rknd) in the United States for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged two months and older.

Global Pharma | 15/09/2025 | By Dineshwori |  204